Trade Medivir B - MEDIVIR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.017053% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.005169% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 100 | ||||||||
| Currency | SEK | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Sweden | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.56 |
| Open | 1.64 |
| 1-Year Change | -38.35% |
| Day's Range | 1.6 - 1.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 1.56 | -0.02 | -1.27% | 1.58 | 1.58 | 1.54 |
| Apr 23, 2025 | 1.56 | -0.08 | -4.88% | 1.64 | 1.64 | 1.56 |
| Apr 22, 2025 | 1.60 | -0.08 | -4.76% | 1.68 | 1.70 | 1.60 |
| Apr 17, 2025 | 1.68 | -0.02 | -1.18% | 1.70 | 1.72 | 1.66 |
| Apr 16, 2025 | 1.70 | 0.00 | 0.00% | 1.70 | 1.90 | 1.70 |
| Apr 15, 2025 | 1.60 | 0.02 | 1.27% | 1.58 | 1.60 | 1.58 |
| Apr 14, 2025 | 1.24 | 0.00 | 0.00% | 1.24 | 1.24 | 1.22 |
| Apr 11, 2025 | 1.24 | 0.00 | 0.00% | 1.24 | 1.26 | 1.20 |
| Apr 10, 2025 | 1.26 | -0.02 | -1.56% | 1.28 | 1.28 | 1.26 |
| Apr 9, 2025 | 1.16 | -0.04 | -3.33% | 1.20 | 1.20 | 1.16 |
| Apr 8, 2025 | 1.18 | 0.00 | 0.00% | 1.18 | 1.20 | 1.14 |
| Apr 7, 2025 | 1.14 | 0.00 | 0.00% | 1.14 | 1.14 | 1.14 |
| Apr 4, 2025 | 1.26 | 0.02 | 1.61% | 1.24 | 1.26 | 1.24 |
| Apr 3, 2025 | 1.22 | -0.02 | -1.61% | 1.24 | 1.24 | 1.22 |
| Apr 2, 2025 | 1.26 | -0.02 | -1.56% | 1.28 | 1.30 | 1.24 |
| Apr 1, 2025 | 1.26 | -0.04 | -3.08% | 1.30 | 1.30 | 1.26 |
| Mar 26, 2025 | 1.34 | 0.00 | 0.00% | 1.34 | 1.36 | 1.32 |
| Mar 25, 2025 | 1.34 | 0.02 | 1.52% | 1.32 | 1.34 | 1.32 |
| Mar 24, 2025 | 1.34 | -0.04 | -2.90% | 1.38 | 1.38 | 1.32 |
| Mar 21, 2025 | 1.44 | 0.00 | 0.00% | 1.44 | 1.48 | 1.44 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Medivir Company profile
About Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.
Equity composition
01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).
| Industry: | Bio Therapeutic Drugs |
Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com